16 completed. 16 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 16 |
| Phase 2 | 5 | Completed 5 |
Follow Poly-ICLC: new trials by email Literature Review of Poly-ICLC trials Research Report on Poly-ICLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma Dendritic Cell Tumor Cell Lysate Vaccine, Pembrolizumab, Placebo Administration - Recurrent Glioblastoma | Phase 1 | Completed | Jonsson Comprehensive Cancer Center | 46 | 2020-01-08 | 2026-08-31 |
| A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer NEO-PV-01, Pembrolizumab, Adjuvant - Carcinoma, Non-Small-Cell Lung, Lung Cancer | Phase 1 | Completed | BioNTech US Inc. | 38 | 2018-05-04 | 2021-02-26 |
| DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Decitabine, Laboratory Biomarker Analysis - Acute Myeloid Leukemia, Blasts 30 Percent or Less of Bone Marrow Nucleated Cells | Phase 1 | Completed | Roswell Park Cancer Institute | 8 | 2018-03-27 | 2026-02-27 |
| Pembrolizumab + Poly-ICLC in MRP Colon Cancer pembrolizumab, Poly-ICLC - Metastatic Colon Cancer, Solid Tumor | Phase 1 / Phase 2 | Completed | Asha Nayak | 42 | 2018-01-10 | 2024-06-07 |
| A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers Durvalumab, Tremelimumab, Poly-ICLC - Head and Neck Squamous Cell Carcinoma, Breast Cancer | Phase 1 / Phase 2 | Completed | Ludwig Institute for Cancer Research | 58 | 2016-12-28 | 2022-12-02 |
| A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer NEO-PV-01, Nivolumab, Adjuvant - Urinary Bladder Cancer, Bladder Tumors | Phase 1 | Completed | BioNTech US Inc. | 34 | 2016-10-01 | 2021-02-25 |
| Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies Peptides, Poly-ICLC, Lenalidomide - Solid Tumors | Phase 1 | Completed | Nina Bhardwaj | 13 | 2016-04-01 | 2021-01-11 |
| DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Epacadostat, Laboratory Biomarker Analysis - Fallopian Tube Carcinoma, Ovarian Carcinoma | Phase 1 / Phase 2 | Completed | Roswell Park Cancer Institute | 40 | 2014-10-10 | 2023-02-24 |
| A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma Poly-ICLC, Peptides - Melanoma | Phase 1 | Completed | Patrick Ott, MD, PhD | 15 | 2014-04-01 | 2025-12-29 |
| In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy rhuFlt3L/CDX-301, Poly-ICLC - Low-Grade B-cell Lymphoma | Phase 1 / Phase 2 | Completed | Joshua Brody | 21 | 2014-01-03 | 2022-09-22 |
| DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Decitabine, Laboratory Biomarker Analysis - Acute Myeloid Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia | Phase 1 | Completed | Roswell Park Cancer Institute | 9 | 2013-07-30 | 2022-07-22 |
| A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic Adenocarcinoma Poly-ICLC, dendritic cell - Pancreatic Adenocarcinoma Non-resectable | Phase 1 | Completed | Medical University of South Carolina | 12 | 2012-08-01 | 2016-12-15 |
| DCVax Plus Poly ICLC in Healthy Volunteers DCVax-001, Poly-ICLC, Placebo - HIV-1 Infection, HIV Infection | Phase 1 | Completed | Rockefeller University | 43 | 2010-05-01 | 2014-05-08 |
| A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 CDX-1401 in combination with Resiquimod and/or Poly-ICLC, CDX-1401, Resiquimod - Advanced Malignancies | Phase 1 / Phase 2 | Completed | Celldex Therapeutics | 70 | 2009-09-01 | 2016-06-27 |
| A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric Gliomas HLA-A2 restricted glioma antigen peptides vaccine, Poly-ICLC - Newly Diagnosed Pediatric Pontine Glioma, Newly Diagnosed Pediatric High Grade Glioma | Phase 1 | Completed | James Felker | 60 | 2009-02-01 | 2024-12-06 |
| Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study Poly-ICLC - Influenza, Severe Acute Respiratory Distress Syndrome | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 57 | 2008-03-24 | 2018-07-05 |
Melanoma (4) · Carcinoma, Non-Small-Cell Lung (3) · Urinary Bladder Neoplasms (3) · Breast Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Leukemia, Myelomonocytic, Chronic (2) · Lung Neoplasms (2) · Myelodysplastic Syndromes (2) · Ovarian Neoplasms (2) · Sarcoma (2) · Adenocarcinoma (1) · Anemia, Refractory (1) · Carcinoma, Merkel Cell (1) · Chondrosarcoma (1) · Colonic Neoplasms (1)
Roswell Park Cancer Institute (3) · BioNTech US Inc. (2) · Asha Nayak (1) · Celldex Therapeutics (1) · James Felker (1) · Jonsson Comprehensive Cancer Center (1) · Joshua Brody (1) · Ludwig Institute for Cancer Research (1) · Medical University of South Carolina (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Nina Bhardwaj (1) · Patrick Ott, MD, PhD (1) · Rockefeller University (1)
United States (16)
Elizabeth Griffiths (2) · Mark DeMario, MD (2) · Nina Bhardwaj, MD, PhD (2) · Asha Nayak, MD (1) · Craig L Slingluff, Jr., MD (1) · Emese Zsiros, MD (1) · James Felker, MD (1) · Joshua Brody, MD (1) · Patrick Ott, MD, PhD (1) · Richard T Davey, M.D. (1) · Sarah Schlesinger, MD (1) · Sharad Ghamande, MD (1) · Timothy F Cloughesy (1)
PMID 24739759, PMID 24792486, PMID 24888813, PMID 33064988, PMID 33294862, PMID 33479501, PMID 34311780, PMID 40809194
P30CA016056 (1)